Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
Article in Journal for ImmunoTherapy of Cancer (September 2023)
The most recent citing publications are shown below. View all 43 publications that cite this research output on Dimensions.
Article in Journal for ImmunoTherapy of Cancer (September 2023)
Article in Frontiers in Oncology (June 2023)
Article in Biomedicines (April 2023)